Concepedia

Publication | Open Access

Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors

DOIFull Paper Access

74

Citations

16

References

2020

Year

Stéphanie Decary, Pierre‐François Berne, Céline Nicolazzi, Anne‐Marie Lefebvre, Tarik Dabdoubi, Béatrice Cameron, Pierrick Rival, Catherine Devaud, Catherine Prades, Hervé Bouchard,
Clinical Cancer Research

Abstract

On the basis of these preclinical data, the ADC SAR408701 is a promising candidate for development as a potential treatment for patients with CEACAM5-positive tumors.

References

YearCitations

Page 1